I70.2
Conditions
Interventions
Group 1: An additional serum tube (8.5 ml) and an EDTA tube (9ml) will be collected as part of the routine blood sample from patients with peripheral arterial occlusive disease (PAOD) who were refe
Sponsors
Universitätsklinikum Augsburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Competent patients who have been informed about the study both in writing and orally and have agreed to participate. Women and men with PAOD stages IIb-IV who are undergoing either a first intervention with stent placement or a reintervention for stent occlusion. Evidence of high-grade peripheral arterial stenoses demonstrated by duplex ultrasound (FKDS), CT, or MRI.
Exclusion criteria
Exclusion criteria: Patients with a tumor diagnosis Patients with a known coagulation disorder Patients under guardianship Patients with a contraindication to the recommended antiplatelet therapy Patients who have prematurely discontinued or paused the recommended antiplatelet therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Frequency of CHIP Mutations in aarly stent occlusion ( <1year): Determine if CHIP mutations (e.g., TET2 gene) are more frequent in patients experiencing early re-occlusion (within 1 year) after peripheral recanalization with stent implantation compared to a control group with long-term successful outcomes. 2. Correlation between CHIP mutations and early stent occlusions: Evaluate the correlation between the presence of CHIP mutations and early re-occlusions (within 1 year) after stent implantation in patients with peripheral arterial occlusive disease (PAOD) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Increased/decreased levels of certain cytokines Assess if there is a biological correlate in terms of increased or decreased concentrations of specific cytokines associated with early re-occlusions (within 1 year) after peripheral recanalization with stent implantation. 2. Cytokine Concentrations in CHIP carriers vs. Non-CHIP carriers: Compare the plasma concentrations of cytokines between CHIP carriers and non-CHIP carriers, both with and without stent occlusion. | — |
Countries
Germany
Contacts
Public ContactViktoria Peters
Universitätsklinikum Augsburg
Outcome results
None listed